VVT Medical Receives the US FDA’s 510(k) Clearance for ScleroSafe System to Treat Varicosities in Superficial Veins
Shots:
- The US FDA has granted 510(k) clearance for the ScleroSafe platform for efficient, non-thermal, non-tumescent (NT-NT) treatment and management of varicosities in superficial veins in the legs
- VVT’s unique, inverse-action dual syringe injects a sclerosing substance into the vein through one syringe while simultaneously aspirating blood through the second syringe. All within a single motion and with single-hand operation
- The syringe is compatible with both foam and liquid ECA substances. Additionally, ScleroSafe was approved in multiple regions, incl. EU, Australia, Southeast Asia, and South America
Ref: prnewswire | Image: VVT Medical
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
